Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium citrate inhaled - Aridis Pharmaceuticals

Next Previous
Drug Profile

Gallium citrate inhaled - Aridis Pharmaceuticals

Alternative Names: AR 501; gallium(III) citrate; Panaecin

Latest Information Update: 30 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aridis Pharmaceuticals
  • Class Antibacterials; Antifungals; Antivirals; Citrates; Heavy metals; Radioisotopes; Small molecules
  • Mechanism of Action Bacterial growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 20 Dec 2024 Gallium citrate inhaled is available for licensing as of 20 Dec 2024. https://www.aridispharma.com/
  • 13 Mar 2023 Aridis Pharmaceuticals anticipates discussion with US FDA and EMA regarding results of the trial to plan the next study for the filing of a license application
  • 13 Mar 2023 Aridis Pharmaceuticals completes a phase-I/II trials in Cystic fibrosis-associated respiratory tract infections in USA (Inhalation) (NCT03669614) (Aridis Pharmaceuticals pipeline, March 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top